Pfizer, U.S. ink $5.29B deal for possible COVID-19 treatment

The U.S. government will pay drugmaker Pfizer $5.29 billion for 10 million treatment courses of its potential COVID-19 treatment if regulators authorize it, the nation's largest purchase agreement yet for a coronavirus therapy.